Anti-AK2 antibody (ab93856)
- Product nameAnti-AK2 antibodySee all AK2 primary antibodies ...
- DescriptionRabbit polyclonal to AK2
- Tested applicationsWB, IHC-P more details
- Species reactivityReacts with: Human
Peptide from the intermediate residues of Human AK2 protein.
- Positive controlHuman fetal kidney lysate and hepatocarcinoma tissue
- Storage instructionsStore at -20°C. Stable for 12 months at -20°C
- Storage bufferPreservative: 0.02% Sodium Azide
Constituents: PBS, pH 7.4
- Concentration information loading...
- PurityProtein A purified
- Clonality Polyclonal
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab93856 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/200 - 1/1000. Predicted molecular weight: 26 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- FunctionCatalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. This small ubiquitous enzyme involved in energy metabolism and nucleotide synthesis that is essential for maintenance and cell growth. Plays a key role in hematopoiesis.
- Tissue specificityPresent in most tissues. Present at high level in heart, liver and kidney, and at low level in brain, skeletal muscle and skin. Present in thrombocytes but not in erythrocytes, which lack mitochondria. Present in all nucleated cell populations from blood, while AK1 is mostly absent. In spleen and lymph nodes, mononuclear cells lack AK1, whereas AK2 is readily detectable. These results indicate that leukocytes may be susceptible to defects caused by the lack of AK2, as they do not express AK1 in sufficient amounts to compensate for the AK2 functional deficits (at protein level).
- Involvement in diseaseDefects in AK2 are the cause of reticular dysgenesis (RDYS) [MIM:267500]; also known as aleukocytosis. RDYS is the most severe form of inborn severe combined immunodeficiencies (SCID) and is characterized by absence of granulocytes and almost complete deficiency of lymphocytes in peripheral blood, hypoplasia of the thymus and secondary lymphoid organs, and lack of innate and adaptive humoral and cellular immune functions, leading to fatal septicemia within days after birth. In bone marrow of individuals with reticular dysgenesis, myeloid differentiation is blocked at the promyelocytic stage, whereas erythro- and megakaryocytic maturation is generally normal.In addition, affected newborns have bilateral sensorineural deafness. Defects may be due to its absence in leukocytes and inner ear, in which its absence can not be compensated by AK1.
- Sequence similaritiesBelongs to the adenylate kinase family. AK2 subfamily.
- Cellular localizationMitochondrion intermembrane space.
- Adenylate kinase 2 antibodyadenylate kinase 2, mitochondrial antibodyAdenylate kinase isoenzyme 2 antibody
- ADK2 antibodyAK 2 antibodyak2 antibodyATP AMP transphosphorylase antibodyATP-AMP transphosphorylase 2 antibodyEC 22.214.171.124 antibodyKAD2_HUMAN antibodymitochondrial antibody
Anti-AK2 antibody images
ab93856, at a 1/100 dilution, showing cytoplasmic staining of Human AK2 in hepatocarcinoma tissue, by Immunohistochemistry, (Formalin/PFA-fixed paraffin-embedded).
Anti-AK2 antibody (ab93856) at 1/500 dilution + Fetal kidney lysate
Predicted band size : 26 kDa
References for Anti-AK2 antibody (ab93856)
ab93856 has not yet been referenced specifically in any publications.